title: Pharmaceutical development and specification of stereoisomers.
abstract: The pharmaceutical development of chiral drugs requires the activities of many different research and development groups. Guidelines which help to coordinate the activities of these groups and assist in the successful development of compounds with either single or multiple chiral centers are outlined and discussed.
authors.affiliation: Pharmaceutical Research and Development, DuPont Merck Pharmaceutical Company, Wilmington, DE 19880, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Williams
authors.forename: C M
authors.initials: CM
authors.lastname: Riley
authors.forename: K W
authors.initials: KW
authors.lastname: Sigvardson
authors.forename: J
authors.initials: J
authors.lastname: Fortunak
authors.forename: P
authors.initials: P
authors.lastname: Ma
authors.forename: E C
authors.initials: EC
authors.lastname: Nicolas
authors.forename: S E
authors.initials: SE
authors.lastname: Unger
authors.forename: D F
authors.initials: DF
authors.lastname: Krahn
authors.forename: S L
authors.initials: SL
authors.lastname: Bremner
mesh_terms: D002986:Clinical Trials as Topic; D004341:Drug Evaluation / Q000379:methods / Q000592:standards*; D017408:Guidelines as Topic / Q000592:standards*; D006801:Humans; D013237:Stereoisomerism; D009626:Terminology as Topic